omega-n-methylarginine has been researched along with atrasentan in 1 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 358 | 41 | 108 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | atrasentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Homo sapiens (human) | 0.2221 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0001 | |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Endothelin receptor type B | Sus scrofa (pig) | 0.315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lennon, R; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E; Reriani, M; Rihal, C | 1 |
1 trial(s) available for omega-n-methylarginine and atrasentan
| Article | Year |
|---|---|
Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.
Topics: Adult; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Coronary Circulation; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Rate; Humans; Kidney; Lipoprotein(a); Male; Microcirculation; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrrolidines; Receptor, Endothelin A; Triglycerides; Uric Acid | 2010 |